Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent High Grade Endometrioid Adenocarcinoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Early research (Phase 1)Active Not RecruitingNCT02627443
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Metastatic Fallopian Tube CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Active Not RecruitingNCT02345265
What this trial is testing

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
Fallopian Tube CarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous Adenocarcinoma+6 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Looking for participantsNCT05920798
What this trial is testing

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaPrimary Peritoneal CarcinosarcomaRecurrent Fallopian Tube Carcinoma+13 more
Mayo Clinic 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT01116648
What this trial is testing

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Who this might be right for
Fallopian Tube CarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+4 more
National Cancer Institute (NCI) 155
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)WithdrawnNCT05295589
What this trial is testing

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04814875
What this trial is testing

Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
THERAPIM PTY LTD 16
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134